Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
35 studies found for:    " November 18, 2009":" December 18, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed ID & Testing in Male Partners
Condition: HIV
Intervention:
22 Completed Exploration of HIV Reservoirs
Condition: HIV-1 Infection
Intervention: Procedure: Rectal mucosa biopsy
23 Completed Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis
Conditions: HIV Infection;   Osteopenia;   Osteoporosis
Intervention:
24 Completed
Has Results
Trichomonas Vaginalis Recurrence Among HIV+ Women
Conditions: Trichomonas Infections;   HIV Infections
Intervention: Drug: Metronidazole
25 Completed Self-Managing HIV and Chronic Disease
Condition: HIV/AIDS
Interventions: Behavioral: Individual Telephone Counseling Intervention;   Other: Group Arm;   Other: Book Arm
26 Completed Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
Conditions: HIV Infection;   Liver Failure;   Evidence of Liver Transplantation
Intervention: Drug: Raltegravir potassium
27 Completed Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients
Conditions: HIV Infection;   Rheumatic Disease;   Cancer;   Transplant;   Pediatrics
Intervention: Biological: Adjuvanted influenza A(H1N1) vaccines
28 Active, not recruiting Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Conditions: AIDS-Related Kaposi Sarcoma;   HIV Infection;   Recurrent Kaposi Sarcoma
Interventions: Drug: Bortezomib;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
29 Completed Contingency Management in the Delivery of HAART to Drug Users in Chennai, India
Conditions: HIV;   Substance Abuse, Intravenous
Interventions: Behavioral: Contingency;   Other: Prize bowl drawings
30 Terminated Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART
Condition: HIV-1
Interventions: Biological: MVA.HIVconsv low dose;   Other: Placebo low dose;   Biological: MVA.HIVconsv high dose;   Other: Placebo high dose
31 Completed Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection
Conditions: H1N1 Influenza Virus;   Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions: Biological: Focetria®;   Biological: Begrivac®
32 Completed Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
Condition: HIV-1 Infection
Interventions: Drug: ART Intensification;   Biological: Immunomodulation
33 Active, not recruiting Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Condition: Infections, Papillomavirus
Interventions: Biological: GSK Biologicals' HPV vaccine 580299;   Biological: Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
34 Unknown  Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients
Conditions: HIV-1 Infection;   Cancer;   Immunosuppression
Intervention: Other: serologic testing
35 Completed Observational Study of the Preventive Trial With HIV-1 Tat Protein
Condition: Healthy Subjects
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-35) Next Page   
Study has passed its completion date and status has not been verified in more than two years.